Asher Bio Raises $55M for Precisely-Targeted Immunotherapies

Asher Bio's Series C Funding

Key Highlights:

• Series C Funding: Raised $55 million in Series C funding to support the development of its precisely-targeted immunotherapies.
• Investors: Led by RA Capital Management, with participation from AstraZeneca, Bristol Myers Squibb, and existing investors.
• Lead Program: Advancing the clinical development of AB248, a novel CD8+ T cell selective IL-2, for the treatment of various solid tumors.

Asher Bio's Target Market

• Target Market: Focus on developing precisely-targeted immunotherapies for cancer, autoimmune diseases, and infectious diseases.
• Oncology Treatment Providers: Collaboration opportunities with oncologists and cancer treatment centers for clinical trials and future partnerships.
• Pharmaceutical Companies: Potential partnerships with pharmaceutical companies for the development and commercialization of immunotherapies.

What Asher Bio Needs to Buy

• Clinical Research and Development Services: Collaborations with research organizations and clinical trial providers for the advancement of their lead program and future therapies.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers to ensure efficient production and distribution of their immunotherapies.
• Regulatory and Compliance Expertise: Engagement with regulatory consultants and experts to navigate the complex regulatory landscape in the biotechnology and pharmaceutical industries.